MARFLOXIN 5 MG TABLETS FOR CATS AND DOGS

Valsts: Īrija

Valoda: angļu

Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)

Nopērc to tagad

Produkta apraksts Produkta apraksts (SPC)
03-02-2017

Aktīvā sastāvdaļa:

MARBOFLOXACIN

Pieejams no:

Krka, d.d., Novo mesto

ATĶ kods:

QJ01MA93

SNN (starptautisko nepatentēto nosaukumu):

MARBOFLOXACIN

Deva:

5 Milligram

Zāļu forma:

Tablets

Receptes veids:

POM

Ārstniecības grupa:

Canine, Feline

Ārstniecības joma:

Marbofloxacin

Ārstēšanas norādes:

Antibacterial

Autorizācija statuss:

Authorised

Autorizācija datums:

2013-05-03

Produkta apraksts

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Marfloxin 5 mg tablets for cats and dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Tablets.
Light brownish yellow, round, biconvex, marble tablets with bevelled
edges and with possible dark and white spots,
scored on one side.
The tablets can be divided into halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats and dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of infections caused by strains of microorganisms
susceptible to marbofloxacin.
In dogs:
skin and soft tissue infections (skinfold pyoderma, impetigo,
folliculitis, furunculosis, cellulitis);
urinary tract infections (UTI) associated or not with prostatitis or
epididymitis;
respiratory tract infections.
In cats:
skin and soft tissue infections (wounds, abscesses, phlegmons);
upper respiratory tract infections.
4.3 CONTRAINDICATIONS
Do not use in dogs aged less than 12 months, or less than 18 months
for exceptionally large breeds of dogs, such as
Great Danes, Briard, Bernese, Bouvier and Mastiffs, with a longer
growth period.
Do not use in cats aged less than 16 weeks.
Do not use in animals with known hypersensitivity to marbofloxacin or
other (fluoro)quinolones or to any of the
excipients of the product.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
A low urinary pH could have an inhibitory effect on the activity of
marbofloxacin. Pyoderma occurs mostly secondary
to an underlying disease, thus, it is advisable to determine the
underlying cause and to treat the animal accordingly.
Each tablet contains:
ACTIVE SUBSTANCE:
Marbofloxacin
5 mg
EXCIPEINTS:
For a full list of excipients, see section 6.1.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_
                                
                                Izlasiet visu dokumentu
                                
                            

Meklēt brīdinājumus, kas saistīti ar šo produktu